TORONTO, Dec. 22 /CNW/ - The common shares of Abattis Biologix Corp.
have been approved for listing on CNSX. The Company has 49,640,500
common shares outstanding all of which is held by the public.
Abattis Biologix is engaged in the research, development and manufacture
of natural botanical formulations which prevent or treat various
influenza strains found in human, avian and mammalian populations. On
April 16, 2009, the Company entered into an agreement with PRB
Pharmaceuticals, Inc. and Pacific Bio-Pharmaceuticals, Inc. for the
purchase of their interest in patents and intellectual property related
to anti viral products designed to prevent avian influenza in humans
Listing and disclosure documents for Abattis Biologix Corp. will be
available in the CNSX Listings Disclosure Hall.
Trading Date: Thursday, December 23, 2010
CUSIP: 00258E 10 8
ISIN: CA 00258E 10 8 8
Applications are being accepted for Market Makers for "FLU".
SOURCE Canadian National Stock Exchange (CNSX)
For further information: For further information:
Radhika at (416) 572-2000 X 2435 or E-mail: email@example.com